BridgeBio Pharma, Inc. 13D

KKR reduced its BridgeBio stake to about 4.7% through a 5,000,000‑share underwritten secondary sale, filing this 13D/A as an exit from 5%+ holder status with no activist plans disclosed.

KKR Genetic Disorder L.P. and affiliated KKR entities now report beneficial ownership of 9,232,739 BridgeBio Pharma, Inc. shares (including 971,768 issuable upon conversion of preferred stock), representing approximately 4.7% of outstanding common stock, after selling 5,000,000 shares in an underwritten secondary offering at a net price of $77.415 per share and consequently falling below the 5% reporting threshold; the filing describes a completed liquidity transaction and a short lock-up, with no activist or control-seeking intentions stated.

Filing Facts

CIK

1743881

Ticker

BBIO

Form

13D

Source Type

fda

Accession

0001140361-26-033404

Alert Tier

8